Certara, Inc. (CERT)
| Market Cap | 908.50M |
| Revenue (ttm) | 419.75M |
| Net Income (ttm) | -15.10M |
| Shares Out | 155.56M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | 14.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,571,420 |
| Open | 5.41 |
| Previous Close | 5.49 |
| Day's Range | 5.41 - 5.92 |
| 52-Week Range | 4.45 - 13.88 |
| Beta | 1.49 |
| Analysts | Buy |
| Price Target | 7.48 (+28.08%) |
| Earnings Date | Aug 5, 2026 |
About CERT
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scient... [Read more]
Financial Performance
In 2025, Certara's revenue was $418.84 million, an increase of 8.75% compared to the previous year's $385.15 million. Losses were -$1.60 million, -86.76% less than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $7.48, which is an increase of 28.08% from the latest price.
News
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's execu...
Certara announces CFO transition; affirms FY26 guidance
Certara (CERT) “announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effective as of the end of the day on…
Certara Announces CFO Transition
RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified th...
Leerink says Certara peer acquisition supports higher multiple
Leerink sees Certara’s (CERT) valuation as overly depressed given what remains a highly profitable entity with multiple long-term growth drivers. This morning’s acquisition of peer Simulations Plus (S...
Certara Transcript: Jefferies Global Healthcare Conference 2026
The company has realigned into two strategic segments, ACE and MID3, to drive growth and operational clarity. AI is being integrated across all products, with a focus on leveraging regulatory expertise and data assets. Strong software growth, ongoing R&D investment, and regulatory tailwinds support expansion in both small and large molecule markets.
Certara Transcript: RBC Capital Markets Global Healthcare Conference 2026
Leadership emphasized deep scientific expertise and a flexible business model, with AI integration and regulatory trends driving growth. Positive biotech funding and regulatory tailwinds support robust demand, while operational changes and cost actions aim to deliver double-digit growth and stable margins by 2026.
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followin...
Certara Transcript: AGM 2026
The meeting saw the re-election of three directors, ratification of the auditor, and approval of executive compensation. Shareholders participated virtually, and all proposals passed by majority vote. Voting results will be filed with the SEC.
Certara price target lowered to $6 from $7 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Certara (CERT) to $6 from $7 and keeps a Market Perform rating on the shares. The company’s Q1 results…
Certara price target lowered to $8 from $10 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Certara (CERT) to $8 from $10 and keeps a Hold rating on the shares. The firm notes the company reported a soft quarter…
Certara price target lowered to $9 from $10 at Stephens
Stephens lowered the firm’s price target on Certara (CERT) to $9 from $10 and keeps an Overweight rating on the shares. The R&MW divestiture better aligns Certara around differentiated MIDD/biosimulat...
Certara price target lowered to $6 from $7 at Baird
Baird analyst Joe Vruwink lowered the firm’s price target on Certara (CERT) to $6 from $7 and keeps a Neutral rating on the shares.The firm updated its model following Q1…
Certara price target lowered to $10 from $11 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Certara (CERT) to $10 from $11 and keeps an Equal Weight rating on the shares. A rebound in software and “disappointment” in…
Certara trading halted, volatility trading pause
09:31 EDT Certara (CERT) trading halted, volatility trading pause
Certara price target lowered to $6.50 from $8 at Barclays
Barclays lowered the firm’s price target on Certara (CERT) to $6.50 from $8 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post the…
Certara Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 1% year-over-year, with strong software bookings and continued investment in AI and platform innovation. The company completed a major divestiture, reorganized around two growth areas, and reaffirmed full-year guidance, expecting stronger performance in the second half.
Certara Slides: Q1 2026
Certara has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Certara Earnings release: Q1 2026
Certara released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Certara Quarterly report: Q1 2026
Certara has published its Q1 2026 quarterly earnings report on May 11, 2026.
Certara reports Q1 adjusted EPS 9c, consensus 11c
Reports Q1 revenue $106.9M, consensus $106.1M. “I am pleased with the progress we made in my first quarter at Certara (CERT),” said CEO Jon Resnick “We are taking decisive steps…
Certara sees FY26 adjusted EPS 35c-41c, consensus 45c
Sees FY26 revenue $395M-$405M, consensus $425.74M.
Certara Reports First Quarter 2026 Financial Results
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writi...
Certara announces strategic partnership with Altasciences
Altasciencese and Certara (CERT) announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human tria...
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)-- #Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug dev...